Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05766384 · ClinicalTrials.gov registry record
Hyperpolarized 129Xe MRI Lung Health Cohort
A clinical trial of Healthy, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- 260
- Enrollment target
- 6
- Study locations
NCT05766384: Recruiting study of Healthy, sponsored by University of Kansas Medical Center.
NCT05766384 is a study of Healthy that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 260 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05766384, a study of Healthy, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- 260 participants
- Enrollment target
- 6
- Study locations
Study Summary
A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.
Primary Outcome
Correlation of Xe-MRI with FEV1/FVC and other measures of lung function
Conditions Studied
Interventions
- DRUG Hyperpolarized Xe129
Study Locations (6)
Texas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Center - Houston
Illinois
- University of Illinois-Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2027-03-31 |
What NCT05766384 shows while recruiting
NCT05766384 is an observational study that tracks outcomes without assigning an intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized Xe129 is the first listed.
NCT05766384 lists 6 locations in 5 states (Texas, Illinois, Iowa).
Frequently Asked Questions
What is clinical trial NCT05766384 about?
NCT05766384 is a clinical study titled "Hyperpolarized 129Xe MRI Lung Health Cohort". A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to ch...
What is the current status of trial NCT05766384?
This trial is currently recruiting. The enrollment target is 260 participants. The study started on 2023-11-30. Estimated completion is 2027-03-31.
What conditions does trial NCT05766384 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05766384?
The interventions under investigation include: Hyperpolarized Xe129 (DRUG).
Who is sponsoring clinical trial NCT05766384?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05766384 being conducted?
This trial has 6 study locations across Illinois, Iowa, Kansas, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05766384's enrollment target sits among peer trials
260 96th of 1090 higher than 994 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI